Sudeep Pharma Ltd.
Fundamentals
- Market cap
- ₹9,140 cr
- P/E
- 52.86×
- ROE
- 28.13%
- Debt / equity
- 0.27
- Div yield
- 0.18%
- 52-week range
- 524.05 — 882.40
Company snapshot
Sudeep Pharma Ltd.
Pharmaceuticals
₹7,586 cr
P/E 43.88×
Latest quarter · Mar 2026
Sales₹182 cr
Net profit₹49 cr
Op. margin+34.3%
EPS₹4.33
Strength & growth
Debt / equity0.27×
Current ratio2.43×
The timeline — 3 notes on Sudeep Pharma Ltd.
May 2026
- 22 May 26 · 12:08 PM IST Brief Brief · Concalls · Mid cap
Sudeep Pharma's Nandesari plant is delayed. Working capital is spiking.
Revenue grew 27.9% to ₹642.6 cr, but the working-capital cycle has blown out to 213 days. A delayed greenfield plant adds to the pressure.
- 21 May 26 · 4:21 PM IST Brief Brief · Earnings · Mid cap
Sudeep Pharma FY26: Revenue up 28%, PAT at ₹174 cr
Speciality ingredients segment drives strong performance; company recommends ₹1.50 per share final dividend.
- 21 May 26 · 4:07 PM IST Brief Brief · Earnings · Mid cap
Sudeep Pharma wraps FY26 with 28% revenue growth, 26% PAT jump
Audited annual numbers confirm strong speciality ingredients demand and NSS Ireland contribution; final dividend of ₹1.50 per share recommended.